Aberrant cell survival is a major obstacle in cancer treatment since tumor cells express enhanced levels of multiple DNA damage repair and cell cycle arrest-related genes, including PIDD, and thereby challenge therapeutic interventions [131]. The gene discussed is PIDD1; the disease is neoplasm.